TY - JOUR T1 - Precision Prostate Cancer Screening with a Polygenic Risk Score JF - medRxiv DO - 10.1101/2020.08.23.20180570 SP - 2020.08.23.20180570 AU - Tõnis Tasa AU - Mikk Puustusmaa AU - Neeme Tõnisson AU - Berit Kolk AU - Peeter Padrik Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180570.abstract N2 - Prostate cancer (PC) is the second-most common type of cancer and the fifth-leading cause of cancer-related death in men worldwide. Genome-wide association studies have identified numerous genetic variants (SNPs) independently associated with PC. The effects of such SNPs can be combined into a single polygenic risk score (PRS). Stratification of men according to PRS could be applied in secondary prevention. We aimed to construct a PRS model and to develop a pipeline for personalized prostate cancer screening.Previously published PRS models for predicting the risk of prostate cancer were collected from the literature. These were validated on the Estonian Biobank (EGC) consisting of a total of 16,390 quality-controlled genotypes with 262 prevalent and 428 incident PC cases and on 209 634 samples in the UK Biobank with 3254 prevalent cases and 6959 incident cases. The best performing model was selected based on the AUC in prevalent data and independently validated in both incident datasets. Using Estonian PC background information, we performed absolute risk simulations and developed individual risk-based clinical follow-up recommendations.The best-performing PRS included 121 SNPs. The C-index of the Cox regression model associating PC status with PRS was 0.641 (SE = 0.015) with a hazard ratio of 1.65 (95% confidence interval 1.51 – 1.81) on the incident EGC dataset. The model is able to identify individuals with more than a 3-fold risk increase. The risk of an average 45-year old could be attained by individuals between the ages of 41 and 52. A 41-year old male on the 95th percentile has the same risk as an average 45-year old but by age 55, he has attained the same genetic risk as an average 68-year-old.PRS is a powerful predictor of prostate cancer risk that can be combined with current non-invasive practices of PC screening. We have developed PRS-based recommendations for personalized PSA testing. Our approach is easily adaptable to other nationalities by using population-specific background data of other genetically similar populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOU Antegenes has received a grant from the EIT Health The Digital Sandbox program and additional Innovation Voucher funding meant for business development of small and medium sized Estonian enterprises.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Estonian Genome Center: All human research was approved by the Research Ethics Committee of the University of Tartu, and conducted according to the Declaration of Helsinki and Human Research Act. All participants provided written informed consent to participate in the Estonian Biobank. UK Biobank: The UK Biobank study was approved by the North West Multi-Centre Research Ethics Committee (UK Biobank reference: 16/NW/0274). All participants provided written informed consent to participate in the UK Biobank study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual level genotype and phenotype data from Estonian Biobank or UK Biobank can not be explicitly shared. The UK Biobank Resource was used under Application Reference Number 53602. New users can request access to UK Biobank from http://www.ukbiobank.ac.uk/resources/. Similarly, Estonian Biobank data is available by request. Researchers interested in Estonian Biobank can request the access here: https://www.geenivaramu.ee/en/access-biobank http://www.ukbiobank.ac.uk/resources/ https://www.geenivaramu.ee/en/access-biobank ER -